Following this agreement, the company developed and marketed a complete portfolio of tests for the identification and quantification of this mutation (JAK2 MutaScreen(TM) et JAK2 MutaQuant(TM), respectively).
As established by the WHO in January 2008, presence of JAK2 V617F is now one of the major criteria in the diagnostic algorithm for MPN. Introduction of the JAK2 V617F test has lead to a more efficient, simpler and shorter diagnostic work-up in routine practice for a growing number of onco-hematologists worldwide.
Ipsogen's blood cancer diagnostic tools
Pioneer of molecular diagnostics for leukemia, Ipsogen develops and markets worldwide a unique and comprehensive range of tests which targets the most molecular anomalies known in blood cancer, including its rarest forms.
These tests, developed in close cooperation with highly specialized clinical centres, provide information on the type of disease (diagnosis, screening), the aggressiveness of cancer (prognosis), the efficacy of proposed targeted therapies (companion diagnosis) and the course of the cancer being treated (monitoring).
Used routinely in over 50 countries, Ipsogen's molecular diagnostic tools improve leukemias' classification allowing personalized treatments.
About ARUP Laboratories
ARUP Laboratories is a national clinical and anatomic pathology reference
laboratory and an enterprise of the
With 2,400 employees, ARUP offers more than 2,000 tests and test
combinations, ranging from routine screening tests to highly esoteric
molecular and genetic assays, for patients throughout the country. Rather
than competing with its clients for physician office business, ARUP chooses
instead to support clients' existing test menus by offering highly complex
and unique tests, with
|SOURCE Ipsogen SA|
Copyright©2009 PR Newswire.
All rights reserved